Longevity and the Future of Aging: AI Meets Biology with Paul Steven Conyngham

Join Paul Steven Conyngham, Co-founder of Core Intelligence Technologies and a veteran data scientist with 17 years of experience, for a conversation that redefined the boundaries of "citizen science." In 2026, Paul stunned the global medical and tech communities by doing the unthinkable: designing a personalized mRNA cancer vaccine for his rescue dog, Rosie, after a terminal diagnosis. In this episode, we discuss how Paul applied the rigors of machine learning and data strategy to the complex world of genomics, utilizing AI to turn a death sentence into a landmark recovery.🎯 Insights You’ll Learn:The "Rosie" Protocol: How a data scientist used ChatGPT, AlphaFold, and Grok to translate genomic sequencing into a custom cancer vaccine.Democratizing Precision Medicine: Why AI is moving life-saving innovation from elite laboratories into the hands of specialized "citizen scientists."The Data-Biology Pipeline: Treating the genome as code—how to apply machine learning engineering to oncological "recipes."Navigating the Gauntlet: The reality of bridging the gap between a DIY AI discovery and formal collaboration with institutions like the UNSW RNA Institute.Community & Knowledge: Lessons from Paul’s time as Director of the Data Science and AI Association of Australia (DSAI) on building high-impact tech networks.AI-First Product Management: Applying the principles of Core Intelligence Technologies to the most complex product of all—a biological cure.The Sam Altman Citation: What it means for the future of the industry when the leaders of OpenAI look at your work as the new standard for AI's potential.🌍 Why This Matters:For decades, the path from a cancer diagnosis to a personalized vaccine was paved with billions of dollars and years of bureaucratic research. Paul Steven Conyngham proved that in 2026, a seasoned data engineer with the right AI tools can collapse that timeline. His achievement—resulting in a 75% reduction in his dog’s tumor—is more than just a heartwarming story; it is a structural proof of concept. Paul is showing the world that when "AI meets Biology," the primary barrier is no longer the technology, but our ability to organize and act on the data.👤 Expert Background:Co-founder of Core Intelligence Technologies, specializing in AI-first data strategy and product management.Pioneer in Citizen Science, globally recognized for designing the first AI-driven personalized canine mRNA vaccine.Former Director of the DSAI, fostering the national machine learning community in Australia for over 5 years.Senior Data Science Veteran with high-impact roles at Woolworths Group and Wattblock.Founder of the Sydney Machine Learning Group, a cornerstone of the Australian AI ecosystem since 2017.🎙️ Hosted by Gary Fowler, CEO of GSD Venture Studios — global AI entrepreneur, investor, and innovation leader spotlighting founders navigating the realities of building in the AI era.💡 Perfect For:Bio-tech innovators, data scientists, medical researchers, startup founders, and anyone interested in the ethical and practical future of AI-driven healthcare.🚀 Timely Topic:In 2026, Paul Steven Conyngham is the face of a new revolution. If a data scientist can design a vaccine for his dog using off-the-shelf AI, the entire pharmaceutical industry is about to be "rewired." Paul is here to tell us how to prepare for that shift.Subscribe for more global founder conversations from GSD Venture Studios: https://gsdvs.com#AIMeetsBiology #PrecisionMedicine #mRNA #AlphaFold #CitizenScience #DataStrategy #PaulConyngham #GaryFowler #GSDVentureStudios